Aerie Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
45.22 M |
Public Float |
33.52 M |
Aerie Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$5.56 |
Market Cap |
$1.19 B |
Shares Outstanding |
45.92 M |
Public Float |
40.44 M |
Address |
4301 Emperor Boulevard Durham North Carolina 27703 United States |
Employees | - |
Website | http://www.aeriepharma.com |
Updated | 07/08/2019 |
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan. The company was founded by David L. |